Bullous pemphigoid developing upon immune checkpoint inhibition with nivolumab.

Authors	Franziska Grän, Matthias Goebeler, Anja Gesierich
Journal	European journal of dermatology : EJD (Eur J Dermatol) Vol. 29 Issue 4 Pg. 448-449 (Aug 01 2019) ISSN: 1952-4013 [Electronic] France
PMID	31625927 (Publication Type: Journal Article)
Chemical References	Antineoplastic Agents, Immunological Nivolumab
Topics	Antineoplastic Agents, Immunological (adverse effects) Cell Cycle Checkpoints (drug effects) Humans Male Middle Aged Nivolumab (adverse effects) Pemphigoid, Bullous (chemically induced)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!